Login / Signup

Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland.

Andrea Favre-BulleGoran BencinaShujing ZhangRuixuan JiangDaniel AndritschkeArjun Bhadhuri
Published in: Journal of medical economics (2023)
The model demonstrated that pembrolizumab is highly cost-effective versus observation in patients with resected stage IIB/IIC melanoma in Switzerland. The ICER was below the WTP threshold of CHF 100,000, commonly used for cost-effectiveness models in Switzerland.
Keyphrases
  • lymph node
  • advanced non small cell lung cancer
  • early stage
  • replacement therapy
  • smoking cessation